Systemic sterile induced-co-expression of IL-12 and IL-18 drive IFN-γ-dependent activation of microglia and recruitment of MHC-II-expressing inflammatory monocytes into the brain.
Cytokine storm
Interferon-γ
Microglia
Monocytes
Sterile neuroinflammation
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
08
11
2021
revised:
03
01
2022
accepted:
12
01
2022
pubmed:
26
1
2022
medline:
8
4
2022
entrez:
25
1
2022
Statut:
ppublish
Résumé
The development of neuroinflammation, as well as the progression of several neurodegenerative diseases, has been associated with the activation and mobilization of the peripheral immune system due to systemic inflammation. However, the mechanism by which this occurs remains unclear. Here, we addressed the effect of systemic sterile induced-co-expression of IL-12 and IL-18, in the establishment of a novel cytokine-mediated model of neuroinflammation. Following peripheral hydrodynamic shear of IL-12 plus IL-18 cDNAs in C57BL/6 mice, we induced systemic and persistent level of IL-12, which in turn promoted the elevation of circulating pro-inflammatory cytokines TNF-α and IFN-γ, accompanied with splenomegaly. Moreover, even though we identified an increased gene expression of both TNF-α and IFN-γ in the brain, we observed that only IFN-γ, but not TNF-α signaling through its type I receptor, was required to induce both the trafficking of leukocytes from the periphery toward the brain and upregulate MHC-II in microglia and inflammatory monocytes. Therefore, only TNF-α was shown to be dispensable, revealing an IFN-γ-dependent activation of microglia and recruitment of leukocytes, particularly of highly activated inflammatory monocytes. Taken together, our results argue for a systemic cytokine-mediated establishment and development of neuroinflammation, having identified IFN-γ as a potential target for immunomodulation.
Identifiants
pubmed: 35074570
pii: S1567-5769(22)00030-3
doi: 10.1016/j.intimp.2022.108546
pmc: PMC8901210
mid: NIHMS1778201
pii:
doi:
Substances chimiques
Cytokines
0
Interleukin-18
0
Tumor Necrosis Factor-alpha
0
Interleukin-12
187348-17-0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108546Subventions
Organisme : FIC NIH HHS
ID : R01 TW007621
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Références
J Neuroinflammation. 2015 Jun 06;12:114
pubmed: 26048578
J Immunol. 2020 Jan 15;204(2):243-250
pubmed: 31907265
PLoS Pathog. 2019 Jan 4;15(1):e1007456
pubmed: 30608984
Brain. 2013 Nov;136(Pt 11):3427-40
pubmed: 24088808
Sci Transl Med. 2019 Aug 14;11(505):
pubmed: 31413142
Nature. 2003 Feb 13;421(6924):744-8
pubmed: 12610626
Front Immunol. 2019 Jan 29;10:80
pubmed: 30761145
J Neurosci. 2010 Nov 24;30(47):15811-20
pubmed: 21106820
Semin Immunopathol. 2017 Jul;39(5):517-528
pubmed: 28555385
Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):11042-11047
pubmed: 30291189
Curr Pharm Des. 2003;9(24):1981-91
pubmed: 12871184
Nat Neurosci. 2012 Jul 26;15(8):1096-101
pubmed: 22837040
Ann N Y Acad Sci. 2001 Sep;941:177-84
pubmed: 11594571
Proc Natl Acad Sci U S A. 2012 Jul 31;109(31):12728-33
pubmed: 22802629
Trends Neurosci. 2005 Sep;28(9):487-93
pubmed: 16023742
Nat Immunol. 2019 Apr;20(4):407-419
pubmed: 30886419
Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16312-7
pubmed: 22988118
J Immunol. 2005 Mar 1;174(5):2796-804
pubmed: 15728489
Nature. 2020 Jul;583(7817):609-614
pubmed: 32581358
Immunity. 2015 Sep 15;43(3):502-14
pubmed: 26341401
Cell Death Dis. 2019 Mar 8;10(3):233
pubmed: 30850582
Glia. 2013 Jan;61(1):71-90
pubmed: 22674585
Mol Neurodegener. 2016 Mar 03;11:23
pubmed: 26939933
Front Immunol. 2017 Dec 04;8:1666
pubmed: 29255461
J Immunol. 2009 Jul 1;183(1):740-8
pubmed: 19535628
J Immunother. 1999 Mar;22(2):135-44
pubmed: 10093038
Nature. 2017 Feb 1;542(7639):110-114
pubmed: 28150777
Nature. 2018 Apr;556(7701):332-338
pubmed: 29643512
Ann Rheum Dis. 2018 Dec;77(12):1842-1845
pubmed: 30012643
Front Immunol. 2018 Dec 20;9:3022
pubmed: 30619363
Cell. 2021 Apr 15;184(8):2033-2052.e21
pubmed: 33765443
EMBO Mol Med. 2019 Jun;11(6):
pubmed: 31015277
Nat Neurosci. 2006 Jul;9(7):917-24
pubmed: 16732273
Gene Ther. 1999 Jul;6(7):1258-66
pubmed: 10455434
PLoS One. 2014 Feb 28;9(2):e90116
pubmed: 24587231
Mol Neurodegener. 2021 Jun 25;16(1):39
pubmed: 34172073
EMBO J. 2014 Jan 7;33(1):7-22
pubmed: 24357543
Nat Neurosci. 2017 Feb;20(2):136-144
pubmed: 28092660
J Immunol. 2018 Jan 15;200(2):471-476
pubmed: 29246952
J Immunol. 2006 Dec 1;177(11):8103-10
pubmed: 17114485
Front Immunol. 2019 May 24;10:1140
pubmed: 31178867
Science. 2020 Nov 27;370(6520):1034-1035
pubmed: 33243875
Trends Immunol. 2019 Apr;40(4):358-374
pubmed: 30833177
J Immunol. 2000 Feb 15;164(4):1705-12
pubmed: 10657614
Nat Rev Neurosci. 2003 Feb;4(2):103-12
pubmed: 12563281
EMBO Rep. 2020 Mar 4;21(3):e48530
pubmed: 32003148
Brain Behav Immun. 2020 Aug;88:597-605
pubmed: 32335194
Nat Med. 2012 Dec;18(12):1812-9
pubmed: 23178247
Chem Immunol. 1997;68:153-74
pubmed: 9329221
J Immunol. 1995 Mar 15;154(6):2846-54
pubmed: 7876554
Front Immunol. 2018 Apr 17;9:770
pubmed: 29719536